Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Peter L Anderson

Showing results (231-240 of 271) with videos related to

Pageof 28
Sort By:
The Lancet. HIV|October 8, 2017
Daily and non-daily pre-exposure prophylaxis in African women (HPTN 067/ADAPT Cape Town Trial): a randomised, open-label, phase 2 trialLinda-Gail Bekker, Surita Roux, Elaine Sebastien, et al.
AIDS and Behavior|April 12, 2023
Acceptability and Feasibility of Providing Adherence Feedback Based on Tenofovir Diphosphate in Dried Blood Spots: Results from a Pilot Study Among Patients and Providers in Cape Town, South AfricaChristopher M Ferraris, Paul A D'avanzo, Lauren Jennings, et al.
AIDS (London, England)|December 18, 2018
The pharmacokinetics, pharmacodynamics, and mucosal responses to maraviroc-containing pre-exposure prophylaxis regimens in MSMIan McGowan, Timothy Wilkin, Raphael J Landovitz, et al.
The Lancet. HIV|February 15, 2025
Safety and drug quantification of the dapivirine vaginal ring and oral pre-exposure prophylaxis in breastfeeding mother-infant pairs (MTN-043): a phase 3B, open-label, randomised trialLisa M Noguchi, Maxensia Owor, Nyaradzo M Mgodi, et al.
Plos Medicine|February 16, 2023
High PrEP uptake and objective longitudinal adherence among HIV-exposed women with personal or partner plans for pregnancy in rural Uganda: A cohort studyLynn T Matthews, Esther C Atukunda, Moran Owembabazi, et al.
The Journal of Antimicrobial Chemotherapy|August 9, 2020
Pharmacokinetics and renal safety of tenofovir alafenamide with boosted protease inhibitors and ledipasvir/sofosbuvirKristina M Brooks, Jose R Castillo-Mancilla, Mary Morrow, et al.
Journal of Controlled Release : Official Journal of the Controlled Release Society|December 24, 2023
Antiviral potency of long-acting islatravir subdermal implant in SHIV-infected macaquesFernanda P Pons-Faudoa, Nicola Di Trani, Simone Capuani, et al.
Journal of Controlled Release : Official Journal of the Controlled Release Society|April 29, 2023
Changes in local tissue microenvironment in response to subcutaneous long-acting delivery of tenofovir alafenamide in rats and non-human primatesFernanda P Pons-Faudoa, Nicola Di Trani, Simone Capuani, et al.
Pharmaceutics|October 21, 2020
Viral load Reduction in SHIV-Positive Nonhuman Primates via Long-Acting Subcutaneous Tenofovir Alafenamide Fumarate Release from a Nanofluidic ImplantFernanda P Pons-Faudoa, Nicola Di Trani, Antons Sizovs, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|December 26, 2016
Decline in Bone Mass With Tenofovir Disoproxil Fumarate/Emtricitabine Is Associated With Hormonal Changes in the Absence of Renal Impairment When Used by HIV-Uninfected Adolescent Boys and Young Men for HIV Preexposure ProphylaxisPeter L Havens, Charles B Stephensen, Marta D Van Loan, et al.
Pageof 28

Showing results (231-240 of 271) with videos related to

Sort By:
Pageof 28
The Lancet. HIV|October 8, 2017
Daily and non-daily pre-exposure prophylaxis in African women (HPTN 067/ADAPT Cape Town Trial): a randomised, open-label, phase 2 trialLinda-Gail Bekker, Surita Roux, Elaine Sebastien, et al.
AIDS and Behavior|April 12, 2023
Acceptability and Feasibility of Providing Adherence Feedback Based on Tenofovir Diphosphate in Dried Blood Spots: Results from a Pilot Study Among Patients and Providers in Cape Town, South AfricaChristopher M Ferraris, Paul A D'avanzo, Lauren Jennings, et al.
AIDS (London, England)|December 18, 2018
The pharmacokinetics, pharmacodynamics, and mucosal responses to maraviroc-containing pre-exposure prophylaxis regimens in MSMIan McGowan, Timothy Wilkin, Raphael J Landovitz, et al.
The Lancet. HIV|February 15, 2025
Safety and drug quantification of the dapivirine vaginal ring and oral pre-exposure prophylaxis in breastfeeding mother-infant pairs (MTN-043): a phase 3B, open-label, randomised trialLisa M Noguchi, Maxensia Owor, Nyaradzo M Mgodi, et al.
Plos Medicine|February 16, 2023
High PrEP uptake and objective longitudinal adherence among HIV-exposed women with personal or partner plans for pregnancy in rural Uganda: A cohort studyLynn T Matthews, Esther C Atukunda, Moran Owembabazi, et al.
The Journal of Antimicrobial Chemotherapy|August 9, 2020
Pharmacokinetics and renal safety of tenofovir alafenamide with boosted protease inhibitors and ledipasvir/sofosbuvirKristina M Brooks, Jose R Castillo-Mancilla, Mary Morrow, et al.
Journal of Controlled Release : Official Journal of the Controlled Release Society|December 24, 2023
Antiviral potency of long-acting islatravir subdermal implant in SHIV-infected macaquesFernanda P Pons-Faudoa, Nicola Di Trani, Simone Capuani, et al.
Journal of Controlled Release : Official Journal of the Controlled Release Society|April 29, 2023
Changes in local tissue microenvironment in response to subcutaneous long-acting delivery of tenofovir alafenamide in rats and non-human primatesFernanda P Pons-Faudoa, Nicola Di Trani, Simone Capuani, et al.
Pharmaceutics|October 21, 2020
Viral load Reduction in SHIV-Positive Nonhuman Primates via Long-Acting Subcutaneous Tenofovir Alafenamide Fumarate Release from a Nanofluidic ImplantFernanda P Pons-Faudoa, Nicola Di Trani, Antons Sizovs, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|December 26, 2016
Decline in Bone Mass With Tenofovir Disoproxil Fumarate/Emtricitabine Is Associated With Hormonal Changes in the Absence of Renal Impairment When Used by HIV-Uninfected Adolescent Boys and Young Men for HIV Preexposure ProphylaxisPeter L Havens, Charles B Stephensen, Marta D Van Loan, et al.
Pageof 28